Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2007-07-31
2007-07-31
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S134100, C424S135100, C424S145100, C530S387300, C530S388250
Reexamination Certificate
active
10427805
ABSTRACT:
This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
REFERENCES:
patent: 4912207 (1990-03-01), Majerus et al.
patent: 5256770 (1993-10-01), Glaser et al.
patent: 5298599 (1994-03-01), Rezaie et al.
patent: 5466668 (1995-11-01), Glaser et al.
patent: 5506134 (1996-04-01), Soule et al.
patent: 5574007 (1996-11-01), Zushi et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5827824 (1998-10-01), Light et al.
patent: 5863760 (1999-01-01), Light et al.
patent: 5874407 (1999-02-01), Kelley et al.
patent: 5916874 (1999-06-01), Fujiwara et al.
patent: 5986065 (1999-11-01), Wong et al.
patent: 6063763 (2000-05-01), Light et al.
patent: 6274142 (2001-08-01), O'Brien et al.
patent: 6555319 (2003-04-01), Wong et al.
patent: 6632791 (2003-10-01), Light et al.
patent: WO 90/10081 (1990-09-01), None
patent: WO88/09811 (1998-12-01), None
patent: WO01/98352 (2001-12-01), None
Zhang et al. “Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity” (1998) J. Clin. Invest. 101:1301-1309.
Wang et al. “Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation” (2000) J. Biol. Chem. 275:22942-22947.
Skolnick et al., Trends in Biotechnology, 2000, 18(1):34-39.
Whisstock et al., Quarterly Reviews of Biophysics, 2003, 36:307-340.
Janeway et al. Immunobiology, third edition, Garland Publishing Inc., 1997, pp. 3:7-3:9.
Amit et al., 1986, Science 233:747-753.
Rudikoff et al., PNAS USA, 1982, 79:1979-1983.
Stedman's Medical dictionary, 27thedition, 2000, definition of synergism, downloaded Oct. 26, 2006 from thomsonhc.com, 2 pages.
On-line Medical dictionary definition of synergy, downloaded Oct. 26, 2006 from cancerweb.ncl.ac.uk, 1 page.
Faelber et al., “The 1.85 Å resolution Crystal Structures of Tissue Factor in Complex with Humanized Fab D3h44 and of Free Humanized Fab D3h44: Revisiting the Solvation of Antigen Combining Sites”,J. Mol. Biol. (2001) 313:83-97.
Haber et al., “Antibody Targeting as a Thrombolytic Strategy”Ann. N.Y. Acad Sci. (1992) 667:365-381.
Moons et al., “Tissue Factor and Coronary Artery Disease”,Cardiovasc. Res. (2002) 53:313-325.
Gresele et al., “Novel Approaches to the Treatment of Thrombosis”,Trends Pharmacol. Sci. 23:25-32 (2002).
Esmon, “Regulation of Blood Coagulation”,Biochim. Biophys. Acta(2000) 1477:349-360.
Esmon, “The Roles of Protein C and Thrombomodulin in the Regulation of Blood Coagulation”J. Biol. Chem. (1989) 264:4743-4846.
Fuentes-Prior et al., “Structural Basis for the Anticoagulant Activity of the Thrombin-thrombomodulin Complex.”Letters to Nature. vol. 404, pp. 518-525, Mar. 30, 2000.
Clarke et al., “The Short Loop between Epidermal Growth Factor-like Domains 4 and 5 Is Critical for Human Thrombomodulin Function.”The Journal of Biological Chemistry. vol. 268, No. 9, pp. 6309-6315, Mar. 25, 1993.
Hall et al., “Thrombin Interacts with Thrombomodulin, Protein C, and Thrombin-activatable Fibrinolysis Inhibitor via Specific and Distinct Domains.”The Journal of Biological Chemistry. vol. 274, No. 36, pp. 25510-25516, Sep. 3, 1999.
Nagashima et al., “Alanine-scanning Mutagenesis of the Epidermal Growth Factor-like Domains of Human Thrombomodulin Identifies Critical Residues for Its Cofactor Activity.”The Journal of Biological Chemistry. vol. 268, No. 4, pp. 2888-2892, Feb. 5, 1993.
Wang et al., “Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation.”The Journal of Biological Chemistry. vol. 275, No. 30, pp. 22942-22947, Jul. 28, 2000.
Bitonti et al., “Pulmonary Delivery of an Erythropoietin Fc Fusion Protein in Non-human Primates Through an Immunoglobulin Transport Pathway.”PNAS. vol. 101, No. 26, pp. 9763-9768, Jun. 29, 2004.
Dong et al., “P-selectin targeting of the Fibrin Selective Thrombolytic Desmodus Rotundus Salivary Plasminogen Activator αl.”Thromb Haemost. vol. 92, pp. 956-965, 2004.
Adams et al., “Thrombin-cofactor Interactions: Structural Insights into Regulatory Mechanisms.”Arteriosclerosis, Thrombosis, and Vascular Biology. vol. 26, pp. 1738-1745, May 25, 2006.
Dahlback et al., “Blood Coagulation.”The Lancet. vol. 355, pp. 1627-1632, May 6, 2000.
Light David
McLean Kirk
Banner & Witcoff , Ltd.
Bayer Schering Pharma AG
Ewoldt G. R.
Szperka Michael
LandOfFree
Tissue factor targeted thrombomodulin fusion proteins as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue factor targeted thrombomodulin fusion proteins as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue factor targeted thrombomodulin fusion proteins as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782192